> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Report Urges FDA Overhaul for Faster Reviews
- URL: https://www.fdaweb.com/report-urges-fda-overhaul-for-faster-reviews/
- Published: 2026-06-01T12:00:00.000Z
- Updated: 2026-09-14T13:40:14.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5161235

A new policy report is calling for sweeping FDA reforms, arguing that shortening the time required to bring drugs, biologics and medical devices to market could generate trillions of dollars in benefits for patients, innovators and the broader economy.

The report, [*The Multi-Trillion Dollar Opportunity in Reforming the FDA*](https://unleashprosperitynow.com/wp-content/uploads/2026/05/UPN-FDA-Paper-II.pdf?ref=fdaweb.com), was released by the policy group Unleash Prosperity and authored by economists and policy experts including former White House economic adviser **Tomas Philipson**. The paper contends that lengthy FDA requirements for demonstrating product effectiveness — beyond establishing safety — delay patient access to medical innovations and weaken U.S. competitiveness against China.

According to the report, accelerating FDA review timelines by one year could create between approximately $4 trillion and $10 trillion in social value, depending on the methodology used, while reducing development timelines by as much as six years could generate tens of trillions of dollars in cumulative benefits. The authors base those estimates on 2024 U.S. sales of pharmaceuticals and medical devices and economic models that attempt to measure both consumer and producer surplus from medical innovations.

The report argues that FDA's current system places excessive emphasis on premarket demonstrations of efficacy. It suggests that once a product's safety has been established, effectiveness assessments could rely more heavily on post-market evidence collection and private-sector evaluation mechanisms.

A central theme of the paper is growing concern about China's rise as a pharmaceutical research and development hub. The authors cite data indicating that China has dramatically accelerated early-stage drug development, conducts clinical trials at significantly lower cost than the U.S., and has gained market share in global Phase 1 research programs. They argue that regulatory delays in the U.S. risk pushing biomedical innovation and investment overseas.

Among the report's recommendations are expanding the use of external control arms and real-world evidence in clinical trials, extending the FDA's international Project Orbis review model beyond oncology, increasing hiring and compensation flexibility for FDA scientific reviewers, and creating a White House-led "Cancer Warp Speed Office" to coordinate cancer-related activities across federal agencies.

The authors also advocate broader use of artificial intelligence in regulatory review and post-market surveillance, greater reliance on trusted foreign regulatory reviews, expanded use of adaptive clinical trial designs, and reforms that would allow earlier patient access to therapies while requiring more robust post-market monitoring.

Perhaps the most controversial proposal would permit drugs deemed safe to enter the market before the FDA completes traditional effectiveness determinations, with effectiveness certification potentially performed by competing public or private entities. The report argues that such a system could preserve safety oversight while accelerating innovation and giving patients faster access to promising therapies.

While many of the report's proposals would require congressional action or significant regulatory changes, the authors argue that accelerating medical innovation represents one of the largest untapped economic opportunities available to policymakers, with potential benefits measured not only in dollars but also in earlier access to lifesaving treatments.